logo
  

ARIAD Pharma Q4 Loss Widens - Quick Facts

ARIAD Pharmaceuticals, Inc. (ARIA) reported fourth-quarter net loss of $51.8 million or $0.38 per share versus loss of $30.3 million or $0.25 per share a year ago. On average, 14 analysts polled by Thomson Reuters expected the company to report loss of $0.19 per share. Analysts' estimates typically exclude special items.

The wider net loss is primarily due to an increase in operating expenses of $11.8 million, reflecting continued development of the company's product candidates, and an increase of $9.3 million in the non-cash charge related to the revaluation of its warrant liability, reflecting the increase in the market price of its common stock during this period.

Total revenue declined to $78 thousand from last year's $535 thousand. Analysts estimated revenues of $940.00 thousand.

Looking ahead, the company expects 2012 research and development expenses of $146 million to $154 million, reflecting expansion of development activities for ponatinib and AP26113, as well as a modest increase in discovery research.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
McDonald's says equal pay for women is just the beginning, while conforming that the fast-food giant pays women globally 99.85 cents on the dollar for similar work, taking into account legitimate pay drivers such as level, location, experience, and performance. The company added that it is on track to close that identified gap in 2022. Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and...
Follow RTT